Status:

RECRUITING

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

Lead Sponsor:

Teva Branded Pharmaceutical Products R&D LLC

Conditions:

Multiple System Atrophy

Eligibility:

All Genders

30+ years

Phase:

PHASE2

Brief Summary

The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A ...

Eligibility Criteria

Inclusion

  • Completion of the treatment period and the week 48(V9) visit of the double-blind trial (TV56286-NDG-20039) whilst remaining compliant with trial requirements
  • Females of childbearing potential may be included only if they have a negative pregnancy test at the baseline visit
  • Females of childbearing potential whose male partners are potentially fertile (ie, no vasectomy) must use highly effective birth control methods for the duration of the trial and for 28 days after the last does of IMP
  • Males who are potentially fertile/reproductively competent (not surgically \[eg, vasectomy\] or congenitally sterile) and their female partners who are of childbearing potential must use, together with their female partners, highly effective birth control methods for the duration of the trial and for 28 days after the last dose of investigational medicinal product
  • NOTE - Additional criteria apply, please contact the investigator for more information

Exclusion

  • Is a female participant who is pregnant, plans to become pregnant, or is breastfeeding during the trial
  • Is of a vulnerable population (eg, people kept in detention or jail)
  • Is using or consuming any prohibited concomitant medications within the specified exclusionary windows of this trial
  • Note - Additional criteria apply, please contact the investigator for more information

Key Trial Info

Start Date :

September 30 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 17 2029

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT07197866

Start Date

September 30 2025

End Date

May 17 2029

Last Update

December 17 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Teva Investigational Site 15544

Boca Raton, Florida, United States, 33486

2

Teva Investigational Site 15543

Spokane, Washington, United States, 99202